

Yubo Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2883304/publications.pdf>

Version: 2024-02-01

26
papers

1,040
citations

516710

16
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

1826
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells <i>in Vitro</i> and <i>In Vivo</i> through Inhibition of IL-6 Signaling and EMT Reversal. <i>Clinical Cancer Research</i> , 2014, 20, 2714-2726.	7.0	212
2	Characterization of an Asymptomatic Cohort of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infected Individuals Outside of Wuhan, China. <i>Clinical Infectious Diseases</i> , 2020, 71, 2132-2138.	5.8	96
3	Metformin Inhibits the IL-6-Induced Epithelial-Mesenchymal Transition and Lung Adenocarcinoma Growth and Metastasis. <i>PLoS ONE</i> , 2014, 9, e95884.	2.5	89
4	Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF- β 2 signaling pathway. <i>Oncotarget</i> , 2015, 6, 43605-43619.	1.8	86
5	Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. <i>Cancer Letters</i> , 2015, 369, 97-102.	7.2	82
6	Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1369-1375.	1.1	68
7	Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. <i>Lung Cancer</i> , 2018, 118, 105-110.	2.0	53
8	Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. <i>Clinical Cancer Research</i> , 2019, 25, 6967-6975.	7.0	52
9	Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. <i>Cancer Letters</i> , 2019, 452, 191-202.	7.2	48
10	Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway. <i>Oncotarget</i> , 2016, 7, 34442-34452.	1.8	41
11	The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. <i>Lung Cancer</i> , 2020, 146, 165-173.	2.0	32
12	Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. <i>Cancer Medicine</i> , 2019, 8, 7669-7678.	2.8	27
13	Vorinostat and metformin sensitize EGFR-TKI resistant NSCLC cells via BIM-dependent apoptosis induction. <i>Oncotarget</i> , 2017, 8, 93825-93838.	1.8	22
14	Aspirin sensitizes osimertinib-resistant NSCLC cells <i>in vitro</i> and <i>in vivo</i> via Bim-dependent apoptosis induction. <i>Molecular Oncology</i> , 2020, 14, 1152-1169.	4.6	20
15	Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1. <i>Cell Death and Disease</i> , 2020, 11, 111.	6.3	18
16	Metformin sensitized NSCLC cells to osimertinib via AMPK-dependent autophagy inhibition. <i>Clinical Respiratory Journal</i> , 2019, 13, 781-790.	1.6	17
17	A transcriptional miRNA-gene network associated with lung adenocarcinoma metastasis based on the TCGA database. <i>Oncology Reports</i> , 2016, 35, 2257-2269.	2.6	12
18	The Utility of ¹⁸ F-FDG PET/CT for Monitoring Response and Predicting Prognosis after Glucocorticoids Therapy for Sarcoidosis. <i>BioMed Research International</i> , 2018, 2018, 1-6.	1.9	11

#	ARTICLE	IF	CITATIONS
19	Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer. <i>Oncology Letters</i> , 2019, 18, 3159-3169.	1.8	11
20	Hexokinases mediated glycolysis governs susceptibility to crizotinib in ALK-positive non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 3184-3193.	1.9	10
21	Metformin attenuates TGF- β 1-induced pulmonary fibrosis through inhibition of transglutaminase 2 and subsequent TGF- β 2 pathways. <i>3 Biotech</i> , 2020, 10, 287.	2.2	9
22	VPS34 suppression reverses osimertinib resistance via simultaneously inhibiting glycolysis and autophagy. <i>Carcinogenesis</i> , 2021, 42, 880-890.	2.8	9
23	Biological Significance of 18F-FDG PET/CT Maximum Standard Uptake Value for Predicting EGFR Mutation Status in Non-Small Cell Lung Cancer Patients. <i>International Journal of General Medicine</i> , 2021, Volume 14, 347-356.	1.8	7
24	Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib. <i>Frontiers in Oncology</i> , 2022, 12, 875313.	2.8	4
25	Cost-effectiveness analysis of neoadjuvant versus adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer patients during initial treatment phase. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 44.	1.5	3
26	Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 9035-9035.	1.6	1